BIA 3-202

DRUG8 trials

Sponsors

Bial - Portela C S.A.

Conditions

HealthyParkinson's DiseaseParkinson's Disease (PD)

Phase 1

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)

CompletedNCT02763839

Bial - Portela C S.A.Parkinson's Disease

Start: 2001-04-30End: 2001-07-31Updated: 2016-05-05

Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202

CompletedNCT02763800

Bial - Portela C S.A.Parkinson's Disease

Start: 2000-09-30End: 2001-01-31Updated: 2016-05-05

Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202

CompletedNCT02763787

Bial - Portela C S.A.Parkinson's Disease

Start: 2000-04-30End: 2000-06-30Updated: 2016-05-16

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)

CompletedNCT02763852

Bial - Portela C S.A.Parkinson's Disease

Start: 2001-04-30End: 2001-07-31Updated: 2016-05-05

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa

CompletedNCT02774564

Bial - Portela C S.A.Parkinson's Disease

Start: 2005-09-30End: 2005-11-30Updated: 2016-05-19

Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin

CompletedNCT02779348

Bial - Portela C S.A.Healthy

Start: 2006-09-30End: 2006-12-31Updated: 2017-08-24

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

CompletedNCT02778594

Bial - Portela C S.A.Parkinson's Disease (PD)

Start: 2005-09-30End: 2005-11-30Updated: 2016-06-14

Phase 2

Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

CompletedNCT02834507

Bial - Portela C S.A.Parkinson's Disease (PD)

Start: 2005-03-31End: 2005-11-30Updated: 2016-07-15